Clinical Trials

Currently Recruiting

For Muscular Dystropy

  • Saftey And Feasiblilty of Transvenous Limb Perfusion with Normal Saline in Human Muscular Dystophy, Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. [Recruiting patients with Limb-Girdle and Becker MD]

  • Assesment of magnetic resonance imaging and its potential use as an outcome measurement in Duchenne Muscular Dystrophy (DMD) patients. [Recruiting infants and children with DMD]

    • Funding: : NC TraCS # 50KR71104, MDA Clinical Research Training Grant, UNC Department of Neurology Broyhill Research Award
    • Contact: Jane Fan, MD., 919-966-8118
  • DP ARF Ultrasound for Monitoring Muscle Degeneration in Duchenne Muscular Dystrophy. [Recruiting children, ages 5, 7 or 9 with Duchenne Muscular Dystrophy (DMD)]

For Myasthenia Gravis

  • A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients with Generalized Myasthenia Gravis on Standard Therapy

  • A phase II randomized, double-blinded, controlled trial of Methotrexate versus Placebo in Myasthenia Gravis Patients who are considered steroid dependent. [Recruiting MGFA Class II-IV MG patients]

    • Funding: UNC Department of Neurology, University of Kansas Medical Center
    • Contact: Manisha Chopra, MD., (919) 843-7857

Recruitment Pending

  • Investigation of the ability of Otelixizumab to inhibit in vitro antigen-specific T cell responses from Myasthenia Gravis patients. [Recruiting MG patients with anti-AChR antibody]

    • Funding: GlaxoSmithKline Pharmaceuticals, Inc. MG0113510
    • Contact: Manisha Chopra, MD., (919) 843-7857

Recruitment Closed

  • A randomized, double-blind, placebo-controlled, cross-over, multi-center study of eculizumab in patients with generalized Myasthenia Gravis (GMG) who have moderate to severe weakness despite treatments with immunosuppressants. [Recruiting refractory MGFA Class II-IV MG patients]

  • Genome wide association study in Myasthenia Gravis. [Recruiting Caucasians with anti-AChR antibody]

    • Myasthenia Gravis Foundation Association of America
    • Contact: Manisha Chopra, MD., (919) 843-7857